Neurology Program

About Kriya Therapeutics

Kriya Therapeutics is a well-funded, clinical-stage gene therapy company targeting large-market, chronic diseases in ophthalmology, metabolic disorders, and neurology. The company has raised over $900 million, including a $320 million Series D in late 2025, to advance its pipeline and internal manufacturing platform. Led by an experienced team with recent key C-suite appointments, Kriya aims to redefine gene therapy by addressing conditions with high unmet need that impact millions of patients.

Therapeutic Areas

Other Trigeminal Neuralgia Drugs